arrow
S

Sumithira Vasu

The Ohio State University
H指数:22
被引数:2,491

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reduced-Dose Post-Transplant Cyclophosphamide (PTCy 40-40) in Allogeneic Hematopoietic Cell Transplantation

异基因造血细胞移植中低剂量移植后环磷酰胺的应用(PTCy 40-40)

2026-08-230
PRE
Recipient Endothelial IRF1 mediates IFNγ-driven tissue tolerance in mouse models of acute Graft-versus-Host Disease.

受体内皮细胞IRF1介导IFNγ驱动的急性移植物抗宿主病小鼠模型中的组织耐受。

Blood
IF23.1
2026-08-070
OA
Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma

B细胞淋巴瘤CAR T细胞疗法后继发性肉瘤的空间组织分析

2026-07-010
PRE
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial

供者检索与选择策略以促进不同供者检索预后组间可比的移植率:BMT CTN 1702试验报告

2026-01-150
PRE
First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial

一线tagraxofusp治疗可诱导年龄小于50岁的blastic plasmacytoid dendritic cell neoplasm成年患者的持久缓解并延长其生存期:一项2期临床试验的回顾性分析

2025-10-120
OAAI
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

ASTCT、CIBMTR、EBMT和APBMT关于造血细胞移植相关血栓性微血管病(TA-TMA)导向治疗反应标准的共识声明

2025-06-010
OAAI
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

血液恶性肿瘤患者接受CAR T细胞疗法后的第二原发恶性肿瘤

2025-03-180
OA
Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

比较两种骨髓清除性全身照射(MAC-TBI)方案:用于成人血液系统恶性肿瘤异基因干细胞移植的1200 Cgy与800 Cgy TBI剂量比较

BLOOD
IF23.1
2024-11-050
PRE
GATA2-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

GATA2突变AML:接受或不接受异基因干细胞移植患者的临床结局及感染谱

BLOOD
IF23.1
2024-11-050
PRE
Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
2024-06-131
OAAI
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research

移植相关血栓性微血管病的诊断标准和预后评估的统一定义: 代表欧洲血液和骨髓移植学会,美国移植和细胞治疗学会,亚太血液和骨髓移植小组以及国际血液和骨髓移植研究中心的报告

2023-03-0165
OAAI
Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force

将患者和护理人员的声音带入临床试验合唱: BMT CTN患者和护理人员倡导工作组的报告

2023-01-017
OAAI
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012

中心经验与供体类型对结果的影响: 二次分析,血液和骨髓移植临床试验网络1101对应计6月20日开放12对应计2012年6月开放

2022-07-015
OAAI